To determine the effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients
Latest Information Update: 09 Dec 2021
At a glance
- Drugs Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 09 Dec 2021 New trial record
- 29 Nov 2021 Results published in the Vaccine